GEMRX Mutual Fund

NAV$19.59

Fund Essentials - as of Jan 31, 2026

Net Assets
$111M
Expense Ratio
1.78%
Dividend Yield (Current)
4.79%
Holdings
70
Inception Date
May 21, 2012
Fund Family
Aberdeen
Investment Style
••••••••••
Asset Class
••••••••••
Legal Structure
••••••••••
Dividend Frequency
Annually

Performance

YTD+26.40%
1 Year+53.16%
3 Year+21.14%
5 Year+4.07%
10 Year+7.92%

Asset Allocation

Stocks: 95.17%
Cash: 4.63%
Other: 0.20%

Top Holdings

View All →
TickerNameWeight
TSMWF:TWTaiwan Semiconductor Manufacturing 5910.63%
005935:KRSamsung Electronics Pref 0.97.10%
0700:HKTencent Holdings Ltd7.01%
GVMXXState Street Institutional US Government Money Market Fund4.65%
9988:HKAlibaba Group Holding Ltd4.41%
Top 10 Concentration: 48.75%Report Date: Jan 31, 2026
Download all 70 holdings for GEMRX
CSV export with sector, industry & share changes
Get CSV

Dividend Summary

View Details →
Dividend Yield (Current)
4.79%
Frequency
Annually
Latest Distribution
$0.14
-

Peer Comparison

Benchmark
••••••••••
Outperforming by ••••%
Ranked #••• of •,••• funds
This Mutual Fund
+••.••%
Peer Avg
+••.••%
Premium Feature
Sign in to unlock peer comparison, category rankings and more

GEMRX Mutual Fund Overview

GEMRX Mutual Fund (Abrdn Emerging Markets Fund Class R) is managed by Aberdeen with $110.6M in net assets. GEMRX expense ratio is 1.78%, holding 70 positions across sectors including Unknown, Financials, Information Technology. Inception date: 2012-05-21.

GEMRX performance shows a YTD return of 26.40%. The 1-year return is 53.16% and the 5-year return is 4.07%. GEMRX dividend yield stands at 4.79%, paid annually.

GEMRX top holdings include Taiwan Semiconductor Manufacturing 59 (10.6%), Samsung Electronics Pref 0.9 (7.1%), Tencent Holdings Ltd (7.0%), State Street Institutional US Government Money Market Fund (4.7%), Alibaba Group Holding Ltd (4.4%). View all GEMRX holdings, sector breakdown, or dividend history.

GEMRX can be compared against other funds using the overlap calculator or side-by-side comparison tool. GEMRX alternatives are available via the screener, along with tax-loss harvesting opportunities.